Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Weighted Average): 2010-2025

Historic Shares Outstanding (Weighted Average) for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $228.4 million.

  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) rose 20.93% to $228.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $228.4 million, marking a year-over-year increase of 20.93%. This contributed to the annual value of $188.8 million for FY2024, which is 7.92% up from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) stood at $228.4 million, which was down 0.00% from $228.4 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) registered a high of $228.4 million during Q1 2025, and its lowest value of $161.6 million during Q1 2021.
  • For the 3-year period, Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) averaged around $193.7 million, with its median value being $188.8 million (2024).
  • Data for Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY rose of 21.12% (in 2025) over the last 5 years.
  • Lineage Cell Therapeutics' Shares Outstanding (Weighted Average) (Quarterly) stood at $168.6 million in 2021, then increased by 0.84% to $170.0 million in 2022, then climbed by 2.95% to $175.0 million in 2023, then climbed by 7.92% to $188.8 million in 2024, then increased by 20.93% to $228.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $228.4 million for Q3 2025, versus $228.4 million for Q2 2025 and $228.4 million for Q1 2025.